Medical News / ASH Data Supports Mitapivat as a PK Deficiency Treatment

New data presented at the 2022 American Society of Hematology (ASH) Meeting show the use of mitapivat is beneficial for patients with a pyruvate kinase (PK) deficiency. PK deficiency is a rare, hereditary hemolytic anemia caused by a single gene defect encoding the red blood cell-specific form of PK. The condition is often associated with acute and long-term complications, as well as a spectrum of signs and symptoms including jaundice, fatigue, and dyspnea. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

In data presented as a late-breaking abstract during Digestive Disease Week (DDW) 2023 in Chicago, a ... read more
Direct endoscopic necrosectomy at index session, as opposed to the step-up approach, for patients with infected ... read more
Gut dysbiosis is often linked to persistent multi-system symptoms after SARS-CoV-2 infections or post-acute COVID-19 syndrome. In ... read more
The explosion of artificial intelligence has permeated through basically all walks of life, including medicine. In an ... read more